Page last updated: 2024-12-07

rb 6145

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

RB 6145: structure given in first source; prodrug to RSU 1069; PD 144872 is the R-enantiomer of RB 6145 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID125377
CHEMBL ID63754
SCHEMBL ID8855507
MeSH IDM0185823

Synonyms (18)

Synonym
alpha-(((2-bromoethyl)amino)methyl)-2-nitro-1h-imidazole-1-ethanol monohydrobromide
rb 6145
1h-imidazole-1-ethanol, alpha-(((2-bromoethyl)amino)methyl)-2-nitro-, monohydrobromide
CHEMBL63754
ci 1010
rb-6145
129448-97-1
alpha-(((2-bromoethyl)amino)methyl)-2-nitro-1h-imidazole-1-ethanol
SCHEMBL8855507
XPBJPGMCFKYBBV-UHFFFAOYSA-N
1-(2-nitro-1-imidazolyl)-3-(2-bromoethylamino)-2-propanol hydrobromide
rb6145
DTXSID90924105
1-[(2-bromoethyl)amino]-3-(2-nitro-1h-imidazol-1-yl)propan-2-ol--hydrogen bromide (1/1)
122178-49-8
1-(2-bromoethylamino)-3-(2-nitroimidazol-1-yl)propan-2-ol;hydrobromide
1h-imidazole-1-ethanol, alpha-[[(2-bromoethyl)amino]methyl]-2-nitro-, hydrobromide (1:1)
AKOS040747359

Research Excerpts

Overview

RB 6145 is a novel hypoxic cell sensitizer and cytotoxin. Contains both an essential bioreductive nitro group and a bromoethylamino substituent.

ExcerptReferenceRelevance
"RB 6145 is a novel hypoxic cell sensitizer and cytotoxin containing both an essential bioreductive nitro group and a bromoethylamino substituent designed to form an alkylating aziridine moiety under physiological conditions. "( Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).
Binger, M; Workman, P, 1991
)
1.94
"RB 6145 is a pro-drug of the hypoxic cell radiosensitizer RSU 1069 with reduced systemic toxicity. "( Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice.
Adams, GE; Bowler, J; Cole, S; Lorimore, SA; Nolan, J; Stratford, IJ; Wright, EG, 1991
)
2

Pharmacokinetics

ExcerptReferenceRelevance
" Reasoning that this may lie in a more beneficial pharmacokinetic profile, we investigated the plasma pharmacokinetics, tissue distribution and metabolism of RB 6145 in mice using a specially developed reversed-phase HPLC technique."( Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).
Binger, M; Workman, P, 1991
)
0.69

Compound-Compound Interactions

ExcerptReferenceRelevance
"To compare the effect on the RIF-1 murine sarcoma of nine bioreductive agents from five different classes when used in combination with either photodynamic therapy or clamping."( Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT).
Adams, GE; Bradley, JK; Bremner, JC; Naylor, MA; Sansom, JM; Stratford, IJ, 1994
)
0.29
"RIF-1 tumors implanted intradermally in C3H mice were treated with either 50J photodynamic therapy or with 120 min clamping in combination with either misonidazole, pimonidazole, metronidazole, nimorazole, RB6145, RSU1069, SR4233, mitomycin-C, or RB90740."( Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT).
Adams, GE; Bradley, JK; Bremner, JC; Naylor, MA; Sansom, JM; Stratford, IJ, 1994
)
0.29
"RSU1069 produced the greatest anti-tumor activity in combination with both photodynamic therapy and clamping."( Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT).
Adams, GE; Bradley, JK; Bremner, JC; Naylor, MA; Sansom, JM; Stratford, IJ, 1994
)
0.29
"Of the bioreductive agents studied RSU1069, RB6145 and mitomycin-C showed the greatest anti-tumor response in combination with photodynamic therapy."( Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT).
Adams, GE; Bradley, JK; Bremner, JC; Naylor, MA; Sansom, JM; Stratford, IJ, 1994
)
0.29

Dosage Studied

ExcerptRelevanceReference
" and oral dosing and possibly contributed to the acute toxicity."( Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).
Binger, M; Workman, P, 1991
)
0.5
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID232995Differential toxicity expressed as the ratio of C50 (air) to C50 (nitrogen)1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and evaluation of novel electrophilic nitrofuran carboxamides and carboxylates as radiosensitizers and bioreductively activated cytotoxins.
AID47690Cytotoxicity in air (MMT assay).1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and evaluation of novel electrophilic nitrofuran carboxamides and carboxylates as radiosensitizers and bioreductively activated cytotoxins.
AID26663Half-life at pH of 5.5-6.0 at 23 degree Centigrade1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activate
AID1651882Cytotoxicity against human A549 cells incubated for 52 hrs in oxic condition by sulforhodamine B assay2020Journal of natural products, 04-24, Volume: 83, Issue:4
Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.
AID133778Maximum tolerated dose was determined for compound administered intraperitoneally in C3H/He mice1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activate
AID217027Concentration which reduced survival to 1% following incubation 3 hours with V79 mammalian cells under hypoxic (Cnitrogen) conditions1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activate
AID110683In vitro concentration of gamma-radiation to give an enhancement ratio of 1.6 in mice when compared to control V79.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins.
AID47691Cytotoxicity in nitrogen (MMT assay).1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and evaluation of novel electrophilic nitrofuran carboxamides and carboxylates as radiosensitizers and bioreductively activated cytotoxins.
AID217026Concentration which reduced survival to 1% following incubation 3 hours with V79 mammalian cells under aerobic (Cair) conditions1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activate
AID216722Reduction of optical density by 50% compared to controls when assay was performed under nitrogen in Hypoxic V79 Cells.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins.
AID213953Reduction of optical density by 50% compared to controls when assay was performed under air in Hypoxic V79 Cells.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins.
AID47688Molar concentration required to give a sensitizer enhancement ratio of 1.6 in hypoxic CHO (V79) cells.1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and evaluation of novel electrophilic nitrofuran carboxamides and carboxylates as radiosensitizers and bioreductively activated cytotoxins.
AID233560The ratio of C50(AIR) to that of C50(N2).1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins.
AID231786Ratio of concentration which reduced V79 cell survival to 1% under aerobic conditions to that of hypoxic conditions1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activate
AID112714The maximum factor by which the cells were sensitized to radiation in mice1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins.
AID1651884Ratio of GI50 for human A549 cells in oxic condition to GI50 for anoxic condition2020Journal of natural products, 04-24, Volume: 83, Issue:4
Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.
AID115159The maximum tolerated dose described as the highest single intraperitoneal dose which did not produce severe or persistent clinical signs or death of the adult non-tumor bearing mice within 24 hours.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins.
AID1651883Cytotoxicity against human A549 cells incubated for 4 hrs in anoxic condition followed by oxic exposure for 48 hrs by sulforhodamine B assay2020Journal of natural products, 04-24, Volume: 83, Issue:4
Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (36)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's27 (75.00)18.2507
2000's6 (16.67)29.6817
2010's2 (5.56)24.3611
2020's1 (2.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.11

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.11 (24.57)
Research Supply Index3.66 (2.92)
Research Growth Index4.15 (4.65)
Search Engine Demand Index13.88 (26.88)
Search Engine Supply Index3.00 (0.95)

This Compound (15.11)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (5.26%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other36 (94.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]